uniqueld	section
CQ37.1	Other guideline
CQ37.2	Other guideline
CQ37.3	Other guideline
CQ37.4	Other guideline
CQ37.5	Other guideline
CQ37.6	Other guideline
CQ37.7	Other guideline
CQ37.8	Other guideline
CQ37.9	Other guideline
CQ37.10	Other guideline
CQ37.11	Other guideline
CQ1.1	First
CQ1.2	First
CQ1.3	First
CQ1.4	First
CQ1.5	First
CQ1.6	First
CQ1.7	First
CQ1.8	First
CQ1.9	First
CQ1.10	First
CQ1.11	First
CQ1.12	First
CQ1.13	First
CQ1.14	First
CQ1.15	First
CQ1.16	First
CQ2.1	First
CQ2.2	First
CQ2.3	First
CQ2.4	First
CQ2.5	First
CQ2.6	First
CQ2.7	First
CQ2.8	First
CQ2.9	First
CQ2.10	First
CQ2.11	First
CQ2.12	First
CQ2.13	First
CQ2.14	First
CQ2.15	First
CQ2.16	First
-	

CQ3	First
CQ4.1	Second
CQ4.2	Second
CQ4.3	Second
CQ4.4	Second
CQ4.5	Second
CQ4.6	Second
CQ4.7	Second
CQ4.8	Second
CQ4.9	Second
CQ4.10	Second
CQ4.11	Second
CQ4.11	Second
•	
CQ4.13	Second
CQ4.14	Second
CQ4.15	Second
CQ4.16	Second
CQ5.1	Second
CQ5.2	Second
CQ5.3	Second
CQ5.4	Second
CQ5.5	Second
CQ5.6	Second
CQ5.7	Second
CQ5.8	Second
CQ5.9	Second
CQ5.10	Second
CQ5.11	Second
CQ5.12	Second
CQ5.13	Second
CQ5.14	Second
CQ5.15	Second
CQ5.16	Second
CQ6.1	Second
CQ6.2	Second
CQ6.3	Second
CQ6.4	Second
CQ6.5	Second
CQ6.6	Second
CQ6.7	Second
CQ6.8	Second
CQ6.9	Second
CQ6.10	Second
CQ6.11	Second

CQ6.12	Second
CQ6.13	Second
CQ6.14	Second
CQ6.15	Second
CQ6.16	Second
CQ7	Second
CQ8	Stop
CQ9	Stop
CQ10	Stop
CQ11	Stop
CQ12	Stop
CQ13	Pathology yield
CQ14	Pathology yield
CQ15	Pathology yield
CQ16	Quality of
CQ17	Non-
CQ18	Non-
CQ19	Non-
CQ20	Non-
CQ21	Non-
CQ22	Post-CRC
CQ23	Post-CRC
CQ24	Post-CRC
CQ25.1	Serrated polyps
CQ25.2	Serrated polyps
CQ26.1	Serrated polyps
CQ26.2	Serrated polyps
CQ27.1	Serrated polyps
CQ27.2	Serrated polyps
CQ28	Post-EMR/ESD
CQ29	Post-EMR/ESD
CQ30	Post-EMR/ESD
CQ31	Polyposis/famil
CQ32	Other guideline
CQ33	Other guideline
CQ34	Other guideline
CQ35	Other guideline
CQ36	Other guideline
CQ38	Other guideline
CQ39	Other guideline
CQ40	Other guideline

clincalQuestion

What is/are the aim(s) of surveillance?

Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp Who is at increased risk of developing CRC or advanced adenomas post-polypectomy (polyp What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance) What is the evidence that 1st surveillance (as opposed to index colonoscopy polyp clearance)

At what interval should 1st surveillance be performed?

Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? Who is at higher risk of developing CRC or advanced adenomas post-1st surveillance? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk? What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

What is the evidence that 2nd (and subsequent) surveillance reduces future CRC risk?

At what interval should 2nd (and subsequent) surveillance be performed?

At what age can surveillance be stopped without increasing the risk of CRC development?

At what estimate of life expectancy can surveillance be stopped without increasing the risk of CRC

What is the risk of colonoscopy in adults >75 years (or other older age cohort)

When (and in whom) can surveillance be stopped, relating to colonoscopy findings?

What threshold (cut-off) should be used to determine whether surveillance is indicated?

What is the risk of CRC/AA/any adenomas in the general population?

What is the risk of CRC/AA/any adenomas in faecal occult blood test screening population at

What is the risk of CRC/AA/any adenomas in symptomatic patients?

Does a high quality colonoscopy have a significant impact on findings (outcomes) at surveillance

Can FIT be used for surveillance after resection of adenomas?

Can colon capsule be used for surveillance after resection of adenomas?

Can CTC be used for polyp surveillance after curative resection of colorectal cancer?

Can CTC be used for polyp surveillance after previous endoscopic polypectomy?

What is the risk of the cumulative radiation dose incurred by CTC polyp surveillance and CTC polyp

Does surveillance, post-CRC surgical resection, reduce metachronous CRC incidence/mortality?

Does surveillance, post-CRC endoscopic resection, reduce metachronous CRC incidence/mortality?

Does surveillance following surgical resection of CRC metastases reduce mortality?

What is the risk of cancer / advanced neoplasia / neoplasia after detection of a sessile serrated

What is the risk of cancer / advanced neoplasia / neoplasia after detection of a sessile serrated

What is the risk of cancer / advanced neoplasia / neoplasia after detection of a sessile serrated

What is the risk of cancer / advanced neoplasia / neoplasia after detection of a sessile serrated

What is the risk of cancer / advanced neoplasia / neoplasia after detection of serrated polyposis

What is the risk of cancer / advanced neoplasia / neoplasia after detection of serrated polyposis

What is the risk of recurrence after complete (En bloc R0) versus piecemeal EMR

What is the risk of recurrence after complete (En bloc RO) versus piecemeal ESD

What is the risk of early recurrence after EMR

Polyposis/family history follow-up

Patient communication, including: Patient lifestyle modifications; What information should patient

Optical diagnosis – virtual ADR without histology

How should polyp size be measured? Endoscopy vs histology

Colonoscopy risks

Modelling of workload effect of change in surveillance guidelines

How to implement? Validating (and whether prospective or retrospective)

Are there any training aspects?

What are the key unanswered questions? – priorities for research; what affects drop-out / default

population	intervention	comparator	outcome
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
Adults (18	Polyp: High	Polyp: Low	Advanced
Adults (18	Polyp: Villous	Polyp: NO	Advanced
Adults (18	Polyp: Size of	Polyp: Size of	Advanced
Adults (18	Polyp: Number	N/a	Advanced
Adults (18	Polyp:	Polyp: Absence	Advanced
Adults (18	Polyp:	N/a	Advanced
Adults (18	Patient: Male	Patient: Female	Advanced
Adults (18	Patient: Family	Patient: NO	Advanced
Adults (18	Patient:	Patient: NOT in	Advanced
Adults (18	Patient: Older	Patient: NOT in	Advanced
Adults (18	Patient:	N/a	Advanced
Adults (18	Patient: High	Patient: NOT	Advanced
Adults (18	Index	Inadequate/po	Advanced
Adults (18	Index	incompete	Advanced
Adults (18	Index	NOT high	Advanced
Adults (18	Index	no high-	Advanced
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC
Adults (18	Colonoscopic	No surveillance	Long-term CRC

Adults (18	"Longer"	"Shorter"	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Findings at 1st	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Summative	Absence of I	Advanced
Adults (18	Polyp: High	No 2nd	Long-term CRC
Adults (18	Polyp: Villous	No 2nd	Long-term CRC
Adults (18	Polyp: Size of	No 2nd	Long-term CRC
Adults (18	Polyp: Number	No 2nd	Long-term CRC
Adults (18	Polyp:	No 2nd	Long-term CRC
Adults (18	Polyp:	No 2nd	Long-term CRC
Adults (18	Patient: Male	No 2nd	Long-term CRC
Adults (18	Patient: Family	No 2nd	Long-term CRC
Adults (18	Patient:	No 2nd	Long-term CRC
Adults (18	Patient: Older	No 2nd	Long-term CRC
Adults (18	Patient:	No 2nd	Long-term CRC

A I II /40	D 11 1 11 1	N 2 1	
Adults (18	Patient: High	No 2nd	Long-term CRC
Adults (18	Index	No 2nd	Long-term CRC
Adults (18	Index	No 2nd	Long-term CRC
Adults (18	Index	No 2nd	Long-term CRC
Adults (18	Index	No 2nd	Long-term CRC
Adults (18	"Longer"	"Shorter"	Advanced
Adults >75	endoscopic	No surveillance	Subsequent
Adults age >65	endoscopic	No surveillance	•
Adults >75 who	,	No	Subsequent
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
Asymptomatic	colonoscopy	-	Prevalence at
Adults (18+	colonoscopy	-	Prevalence at
Adults (18+	colonoscopy	-	Prevalence at
Adults	High quality	"Standard	Advanced
Adults (>18	FIT surveillance	endoscopic	Subsequent AA
Adults (>18	Capsule	endoscopic	Subsequent AA
Adults 18+	CT	Conventional	Sensitivity and
Adults 18+	CT	Conventional	Sensitivity and
Adults 18+	CT	None	Estimated (a)
adults who	FIT;	absence of	Incidence of
adults who	FIT;	absence of	Incidence of
adults who	FIT;	absence of	Incidence of
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults with a	endoscopic	No surveillance	Any neoplasia
Adults meeting	Endoscopic	Endoscopic	Polyp
Patients	Endoscopic	Endoscopic	Polyp
Patients	Endoscopic	Endoscopic	Polyp
No PICO	No PICO	No PICO	No PICO
Adults (>18	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
patients	size of polyp	visual	assigning an
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
No PICO	No PICO	No PICO	No PICO
- · · - -	- · ·	- · ·	- · ·